天津医药

天津医药 ›› 2016, Vol. 44 ›› Issue (9): 1177-1180.doi: 10.11958/20160213

• 综述 • 上一篇    下一篇

唑来膦酸在乳腺癌中抗肿瘤差别化效应的研究进展

谷振坤,任媛媛,杜晓琅,王晨   

  1. 天津医科大学肿瘤医院药学部， 国家肿瘤医学研究中心， 天津市肿瘤防治重点实验室（邮编 300060）
  • 收稿日期:2016-03-28 修回日期:2016-06-04 出版日期:2016-09-15 发布日期:2016-09-28
  • 通讯作者: 王晨 E-mail:jieyi789@126.com
  • 作者简介:谷振坤（1985）， 女， 硕士， 主管药师， 主要从事肿瘤药物临床应用及耐药机制的研究

Research progress on the anti-tumor differentiation effects of zoledronic acid in breast cancer

GU Zhenkun, REN Yuanyuan, DU Xiaolang, WANG Chen△   

  1. Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Department of Pharmacy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
  • Received:2016-03-28 Revised:2016-06-04 Published:2016-09-15 Online:2016-09-28
  • Contact: WANG Chen E-mail:jieyi789@126.com

PDF (PC)

3835

摘要： 乳腺癌是女性发病率和死亡率较高的恶性肿瘤。 肿瘤复发和远处转移是导致死亡的主要原因。 唑来膦酸（ZOL）具有潜在抑制破骨细胞介导的骨吸收的特性， 既可抑制肿瘤细胞增殖和启动肿瘤细胞凋亡， 又可干扰肿瘤细胞与骨基质的黏附， 从而抑制肿瘤细胞的迁移和侵袭。 一些临床前研究已经证实 ZOL 具有直接抗肿瘤作用， 且在对绝经前和绝经后乳腺癌患者的治疗效果上有差异。 本文就 ZOL 在乳腺癌中抗肿瘤差别化效应的基础及临床研究进展作一综述。

关键词: 乳腺肿瘤, 抗肿瘤药, 临床试验, 唑来膦酸

Abstract: Breast cancer is the highest incidence and mortality of malignant tumor in women. Recurrence and distant metastasis are the main cause of death. Zoledronic acid (ZOL) has the potential to inhibit bone resorption characteristics mediated by osteoclast, which not only could suppress tumor cell proliferation and start the apoptosis of tumor cells, but also might interfere the adhesion of cancer cells to bone matrices, thereby could inhibit the migration and invasion of tumor cells. In some preclinical studies zoledronic acid has been demonstrated to have the direct anti-tumor effects on breast cancer. There are different therapeutic effects in treatment with zoledronic acid between the premenopausal and post-menopausal patients with breast cancer. This review summarized basic and clinical research progress of the anti-tumor differentiation effect of zoledronic acid in breast cancer.

Key words: breast neoplasms, antineoplastic agents, clinical trial, Zoledronic acid